Indianapolis, Indiana | April 13, 2026
Eli Lilly and Company has announced positive topline results from the Phase 3 BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) significantly improved progression-free survival (PFS) when combined with venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The study successfully met its primary endpoint, showing a statistically significant and clinically meaningful benefit, marking a major advancement in time-limited treatment strategies for hematologic cancers. These findings reinforce Jaypirca’s growing role as a next-generation BTK inhibitor in modern oncology and highlight its potential to redefine treatment paradigms in previously treated patients.
Phase 3 Trial Demonstrates Superior Progression-Free Survival
The global, randomized BRUIN CLL-322 trial enrolled 639 patients and compared a combination regimen of pirtobrutinib, venetoclax, and rituximab against a control arm of venetoclax plus rituximab. Results showed that the addition of pirtobrutinib significantly extended progression-free survival, as assessed by an independent review committee, across multiple clinically relevant subgroups.
Notably, the trial included a high proportion of patients previously treated with covalent BTK inhibitors, reflecting real-world clinical practice. While overall survival data remains immature, early trends favor the combination therapy, suggesting potential long-term benefits. Importantly, this study represents the first Phase 3 trial in CLL to outperform a venetoclax-based control regimen, further validating the clinical impact of this novel therapeutic approach.
Innovative BTK Inhibitor Enhances Targeted Therapy Outcomes
Advertisement
Jaypirca is a highly selective, non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, designed to overcome resistance mechanisms associated with earlier-generation therapies. With 300-fold selectivity for BTK, the drug effectively targets malignant B-cells while minimizing off-target effects.
The combination with venetoclax, a BCL-2 inhibitor, and rituximab, an anti-CD20 monoclonal antibody, creates a synergistic treatment strategy that enhances tumor cell death. This approach aligns with the growing emphasis on precision medicine and targeted combination therapies, enabling more effective disease control while offering the advantage of time-limited treatment duration, which is increasingly preferred by both clinicians and patients.
Safety Profile Supports Clinical Use and Regulatory Expansion
The safety profile of the combination regimen was consistent with the known profiles of the individual therapies, with similar rates of adverse events across treatment arms and low discontinuation rates, indicating strong tolerability. Common adverse events included neutropenia, anemia, infections, and fatigue, which were manageable within standard clinical practice. Lilly plans to submit these Phase 3 results to regulatory authorities later in 2026 to support a potential label expansion for Jaypirca, further strengthening its position in the treatment landscape. The study builds on previous successful trials within the BRUIN program, marking the fourth positive Phase 3 study for pirtobrutinib, and reinforcing its potential as a cornerstone therapy in CLL and SLL management.
The BRUIN CLL-322 trial results represent a significant milestone in hematologic oncology, demonstrating that Jaypirca-based combination therapy can deliver superior clinical outcomes in patients with previously treated CLL/SLL. With its innovative mechanism, strong efficacy data, and favorable safety profile, pirtobrutinib is positioned to play a critical role in the future of targeted cancer therapy. As regulatory submissions progress, these findings may lead to expanded treatment options and improved patient outcomes, reinforcing the importance of next-generation precision therapies in oncology.
Source: Eli Lilly press release
